NeOnc Technologies Holdings, Inc., a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers, has announced a significant milestone in its strategic partnership with Quazar Investment. The company has executed a Sub-License Agreement, transferring rights from NeOnc to its Abu Dhabi subsidiary, NuroCure, covering the UAE and the wider GCC and MENA regions for its innovative NEO100 and NEO212 treatments. This agreement is part of a larger $50 million equity investment and expansion plan into the MENA region, as outlined in a non-binding term sheet. The partnership aims to drive institutional capital, enhance market liquidity, and support the launch of clinical trials and infrastructure development across the region. The completion of this partnership is contingent upon meeting several conditions, including the legal establishment of NuroMENA and NuroCure in Abu Dhabi and finalizing necessary offering documents.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。